Actavis Inc (ACT) 298.98 $ACT Aquinox Announces
Post# of 273246
Posted On: 09/08/2016 5:02:16 AM
Actavis Inc (ACT) 298.98 $ACT
Aquinox Announces Executive Appointments
GlobeNewswire - Wed May 25, 8:15AM CDT
Aquinox Pharmaceuticals, Inc. ("Aquinox"
(NASDAQ:AQXP), a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology, is pleased to announce the appointment of Mrs. Abigail L. Jenkins as Chief Commercial Officer and Mr. Paul Brennan as Vice President, Business Development. Mrs. Jenkins will act as our US Business Head at our San Bruno, CA office and lead the design and implementation of the commercialization strategy for AQX-1125 while Mr. Brennan will be responsible for the identification and fostering of corporate alliances to support and compliment our global business strategies.
ACT: 298.98 (-2.94), AQXP: 12.18 (+0.32), PFE: 34.84 (+0.07)
Supernus Enters Into Partial Settlement Agreement with Actavis on Oxtellar XR(R)
GlobeNewswire - Tue May 10, 7:30AM CDT
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, today announced that, pursuant to a confidential partial settlement agreement, it has dismissed two patent infringement actions pending in the U.S. District Court for the District of New Jersey against Actavis Inc. and its subsidiaries. The dismissed actions concerned two of Supernus' Orange Book patents covering Oxtellar XR(R)--U.S. Patent Nos. 8,821,930 and 9,119,791. The parties also agreed to dismiss Actavis' pending appeal (and Supernus' corresponding cross-appeal) of a February 2016 district court ruling that a third Oxtellar XR patent--U.S. Patent No. 8,617,600--is valid, but not infringed by Actavis' proposed generic version of Oxtellar XR. The February 2016 district court decision additionally found that Actavis infringed two other Oxtellar XR Orange Book patents (U.S. Patent Nos. 7,722,898 and 7,910,131), and enjoined Actavis from launching a generic version of Oxtellar XR until at least April 13, 2027. Actavis' appeal of that ruling will proceed as scheduled.
ACT: 298.98 (-2.94), SUPN: 22.51 (+0.32)
Global Human Reproductive Technologie Industry
PR Newswire - Tue Apr 05, 6:40PM CDT
This report analyzes the worldwide markets for Human Reproductive Technologies in US$ Million by the following Product Segments: Contraceptive Technologies, and Infertility Technologies. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Middle East & Africa, and Latin America. Annual estimates and forecasts are provided for the period 2014 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 102 companies including many key and niche players such as -
ACT: 298.98 (-2.94)
United States Pharmaceutical Preparation Market 2015 - Analysis And Forecast to 2020
M2 - Tue Jan 19, 6:27AM CST
Research and Markets (http://www.researchandmarkets.com/research/m9h77d/u_s) has announced the addition of the "U.S. Pharmaceutical Preparation Market - Analysis And Forecast to 2020" report to their offering. The report provides an in-depth analysis of the U.S. Pharmaceutical Preparation market. It presents the latest data of the market size and volume, domestic production, exports and imports, price dynamics and turnover in the industry. In addition, the report contains insightful information about the industry, including industry life cycle, business locations, productivity, employment and many other crucial aspects. The Company Profiles section contains relevant data on the major players in the industry. Product coverage: - Pharmaceutical preparations, affecting neoplasms, the endocrine system, and metabolic diseases, for human use - Pharmaceutical preparations, acting on the central nervous system and the sense organs, for human use - Pharmaceutical preparations, acting on the cardiovascular system, for human use - Pharmaceutical preparations, acting on the respiratory system, for human use - Pharmaceutical preparations, acting on the digestive or the genito-urinary systems, for human use - Pharmaceutical preparations, acting on skin, for human use - Pharmaceutical preparations, vitamin, nutrient, and hematinic preparations, for human use - Pharmaceutical preparations, affecting parasitic and infective diseases, for human use (excluding diagnostics) - Pharmaceutical preparations for veterinary use (including medicinal premixes and medicated pet care products, excluding pet flea and tick products), excluding diagnostics In vivo diagnostic substances Companies mentioned: - Pfizer Inc. - Merck & Co. - Abbott Laboratories - Abbvie Inc. - Eli Lilly and Company - Bristol-Myers Squibb Company - Genentech - Baxter International - Allergan - Biogen - Glaxosmithkline - Celgene Corporation - Hospira - Alere - Perrigo Company - Mylan Inc. - Regeneron Pharmaceuticals - Novartis Corporation - Alexion Pharmaceuticals - Genzyme Corporation - Zoetis - Sanofi US Services - Olympus Partners - Valeant Pharmaceuticals International - Merck Sharp & Dohme Corp. - Glaxosmithkline Holdings (americas) - Wyeth - Astrazeneca Pharmaceuticals - Actavis Inc. - Alcon Laboratories Holding Corporation - Roche Holdings Data coverage: - Market size; - Domestic production, value of shipments; - Key market players and their profiles; - Exports, imports and trade balance; - Import and export prices; - Forecast of the market dynamics in the medium term; - Key industry statistics; - Life cycle of the industry; - Number of establishments and their locations; - Employment data; - Industry productivity. For more information visit http://www.researchandmarkets.com/research/m9h77d/u_s
ABT: 41.90 (-0.26), PRGO: 90.39 (-1.68), ACT: 298.98 (-2.94), PFE: 34.84 (+0.07), LLY: 78.59 (+0.08), BMY: 56.57 (-0.39), VRX.TO: 39.05 (+1.19), AGN: 238.42 (-0.70), BAX: 45.90 (-0.05), MRK: 62.87 (-0.37), ALXN: 125.09 (-0.76), REGN: 399.89 (+1.58), NVS: 80.36 (+0.21), CELGZ: 1.20 (-0.05)
Human Reproductive Technologies Study 2015 - Global Strategic Business Report
M2 - Thu Jan 07, 9:35AM CST
Research and Markets (http://www.researchandmarkets.com/research/g69g82/human) has announced the addition of the "Human Reproductive Technologies - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Human Reproductive Technologies in US$ Million by the following Product Segments: Contraceptive Technologies, and Infertility Technologies. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Middle East & Africa, and Latin America. Annual estimates and forecasts are provided for the period 2014 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 102 companies including many key and niche players such as - Actavis, Inc. (US) - Ansell Limited (Australia) - Agile Therapeutics, Inc. (US) - Bayer HealthCare (Germany) - Church & Dwight Co., Inc. (US) - Cipla Limited (India) - CellCura ASA (Norway) - Cook Medical (US) - CooperSurgical (US) - Ferring Pharmaceuticals (Switzerland) - Fuji Latex Co., Ltd. (Japan) - Genea Biomedx (Australia) - Merck KGAA (Germany) - Okamoto Industries (Japan) - Pfizer Inc. (US) - Progyny, Inc. (US) - Reckitt Benckiser Group Plc. (UK) - Sanofi (US) - Teva Pharmaceutical Industries Ltd. (Israel) - The Female Health Company (US) Key Topics Covered: 1. INDUSTRY OVERVIEW 2. MARKET SEGMENTATION 3. INNOVATIONS IN THE HUMAN REPRODUCTIVE TECHNOLOGIES SPACE 4. TECHNOLOGY OVERVIEW 5. PRODUCT LAUNCHES/APPROVALS 6. RECENT INDUSTRY ACTIVITY 7. FOCUS ON SELECT GLOBAL PLAYERS 8. GLOBAL MARKET PERSPECTIVE Total Companies Profiled: 102 (including Divisions/Subsidiaries - 115) - The United States (28) - Canada (3) - Japan (3) - Europe (34) - - France (1) - - Germany (11) - - The United Kingdom (6) - - Italy (3) - - Rest of Europe (13) - Asia-Pacific (Excluding Japan) (41) - Latin America (3) - Africa (2) - Middle East (1) For more information visit http://www.researchandmarkets.com/research/g69g82/human
CHD: 49.13 (-1.18), ACT: 298.98 (-2.94), PFE: 34.84 (+0.07), TEVA: 51.29 (-0.04)
Emergency Medicine of the Future Demonstrated at ACEP15
PR Newswire - Tue Oct 27, 5:21PM CDT
Demonstrations by nearly 60 companies of cutting-edge technologies and devices are being featured this week in Boston during the ACEP 2015 Scientific Assembly where more than 6,500 emergency physicians are discussing the preeminent issues in emergency medicine and participating in educational courses. 2015 InnovatED is presented by Actavis, athenahealth, and Janssen Pharmaceuticals and allows participants to tour medical innovations in a unique emergency medicine environment.
ACT: 298.98 (-2.94)
Allergan Anti-Infective Portfolio Highlighted in 13 Abstracts at IDWeek 2015
PR Newswire - Thu Oct 08, 6:01AM CDT
Allergan plc (NYSE: ACT) today announced that its infectious disease portfolio will be featured in 13 abstracts highlighting data at IDWeek 2015, which takes place from October 7-11, 2015, in San Diego.
AGN: 238.42 (-0.70), ACT: 298.98 (-2.94), AZN: 33.18 (+0.09)
Cipher announces settlement in patent litigation for Absorica®
CNW Group - Mon Oct 05, 6:00AM CDT
Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company" today announced that the Company, along with its partners, Ranbaxy Pharmaceuticals, Inc. ("Ranbaxy" , a Sun Pharma Company, and Galephar Pharmaceutical Research, Inc. ("Galephar" , have entered into a Settlement Agreement with Actavis Laboratories F1, Inc., Andrx Corp., Actavis, Inc. and Actavis Pharma, Inc. ("Actavis" that dismisses the patent litigation suit relating to Actavis' Abbreviated New Drug Application (ANDA) for a generic version of Absorica® (isotretinoin capsules).
CPH.TO: 5.40 (+0.01), ACT: 298.98 (-2.94), CPHR: 4.26 (+0.06)
Depomed Files New Patent Infringement Lawsuit Against NUCYNTA(R) ER ANDA Filer
PR Newswire - Tue Sep 15, 7:00AM CDT
Depomed, Inc. (NASDAQ: DEPO) today announced that it has filed a new patent infringement lawsuit in the United States District Court for the District of New Jersey against Actavis Elizabeth LLC, Actavis, Inc. and Actavis LLC ("Actavis" . Actavis previously filed an Abbreviated New Drug Application (ANDA) with the FDA to market generic Nucynta® ER (tapentadol hydrochloride, extended release) tablets and it served Paragraph IV certifications on the patents then listed in FDA's Orange Book for Nucynta® ER. At the time, Janssen Pharmaceuticals, Inc. owned the rights to Nucynta® ER and it filed a patent infringement suit against Actavis. Subsequently, U.S. Patent No. 8,536,130 ("'130 patent" issued and was listed in the Orange Book for Nucynta® ER, but Actavis did not file a Paragraph IV certification on this patent. In its new lawsuit, Depomed claims that Actavis's proposed generic product would infringe the '130 patent if its generic products are approved. The '130 patent does not expire until September 22, 2028, subject to additional exclusivity for pediatric studies.
ACT: 298.98 (-2.94), DEPO: 21.79 (+0.70)
Global Parenteral Nutrition Industry
PR Newswire - Thu Aug 06, 3:32PM CDT
This report analyzes the worldwide markets for Parenteral Nutrition in US$ Million. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Middle East/Africa, and Latin America. Annual estimates and forecasts are provided for the period 2014 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 25 companies including many key and niche players such as -
ACT: 298.98 (-2.94)
Moderate Pain Market Analysis 2015 - Global API Manufacturers and Phase III Pipeline Assessment
M2 - Thu Aug 06, 10:08AM CDT
Research and Markets (http://www.researchandmarkets.com/research/qqg32p/moderate_pain) has announced the addition of the "Moderate Pain- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment" report to their offering. Moderate Pain- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014 provides comprehensive insights about phase III pipeline drugs and marketed drugs across the indication. A key objective of the report is to establish the understanding for API Manufacturers for marketed and Phase III pipeline drugs across the different countries and regions. While the leading brands, companies and chemicals are considered thoroughly, the report also provides details on the drug master filings across the US, Europe and Asia specifically China and India. The research, analysis also presents the global sales forecasts data till 2015. The report is also giving insight about the patent and exclusivity details of all the drugs across the indication. Key Topics Covered: - Indication Overview - Marketed Drugs Assessment - Marketed Details of Drugs by Application Type - Marketed Details of Drugs (NDA) by Marketing Status - Marketed Details of Drugs by Patent Expiration Timeline - The Active Pharmaceutical Ingredient (API) Manufacturers Assessment - The API Manufacturers by the United States Drug Master File (US DMF) Status - The API Manufacturers by the US DMF Status (Drug Specific) - The Active Pharmaceutical Ingredient (API) Manufacturers Assessment for Phase III Pipeline Drugs - The API Manufacturers by the US DMF Status (Drug Specific) - Drugs Market Data and Forecasted Sales Figures (2011-2015) - Marketed Drugs Information - Drugs Description - Route of Synthesis - Global Active Pharmaceutical Manufacturers - Approval Status - Patent and Exclusivity Details - Company Overview - Phase III Drugs Information - Phase III Drugs Description - The United States Drug Master Filings (US DMF) - Discontinued Drugs Information Companies Mentioned - Pfizer Inc. - Janssen Pharmaceutica, Inc. - Purdue Pharma L.P. - Prasco Laboratories - American Regent, Inc. - Caraco Pharmaceutical Laboratories, Ltd. - Merck & Co., Inc. - Novartis Pharmaceuticals Corporation - Actavis Inc. - Mallinckrodt Pharmaceuticals Generics - Shionogi Inc. - Mylan Inc. - Hospira, Inc. - Medicis Pharmaceutical Corporation For more information visit http://www.researchandmarkets.com/research/qq...erate_pain
ACT: 298.98 (-2.94), PFE: 34.84 (+0.07), MRK: 62.87 (-0.37), NVS: 80.36 (+0.21)
Lower Respiratory Tract Infections Market Analysis 2015 - Global API Manufacturers and Phase III Pipeline Assessment
M2 - Thu Aug 06, 9:52AM CDT
Research and Markets (http://www.researchandmarkets.com/research/396bfs/lower_respiratory) has announced the addition of the "Lower Respiratory Tract Infections- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment" report to their offering. Lower Respiratory Tract Infections- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014 provides comprehensive insights about phase III pipeline drugs and marketed drugs across the indication. A key objective of the report is to establish the understanding for API Manufacturers for marketed and Phase III pipeline drugs across the different countries and regions. While the leading brands, companies and chemicals are considered thoroughly, the report also provides details on the drug master filings across the US, Europe and Asia specifically China and India. The research, analysis also presents the global sales forecasts data till 2015. The report is also giving insight about the patent and exclusivity details of all the drugs across the indication. Reasons to buy - Evaluate the marketing status and exclusivity details of Lower Respiratory Tract Infections key products to exploit opportunities for generic drug development opportunities. - Identify and understand important and diverse types of therapeutics under Phase III development for Lower Respiratory Tract Infections. - Design effective counter-strategies to gain competitive advantage by identifying the key patent expiry details and exclusivity with respect to Lower Respiratory Tract Infections. - API intelligence over marketed drugs for Lower Respiratory Tract Infections and gaining primary intelligence over active ingredients manufacturers across the globe. - API intelligence over leading Phase III pipeline drugs. - Develop and designstrategies by identifying the API manufacturers for Phase III pipeline products to enhance and expand business potential and scope. - Understanding the scope of the Phase III Drugs with nil regulatory filings. - Understanding the chemical route of synthesis of approved drugs for Lower Respiratory Tract Infections. - Uncovering opportunities in the rapidly growing the US markets. Companies Mentioned - Merck & Co., Inc. - Dr. Reddy's Laboratories Limited - Corden Pharma International GmbH - Eli Lilly and Company - Genentech, Inc. - Arbor Pharmaceuticals, Inc. - Bayer AG - Bristol-Myers Squibb Company - Mayne Pharma Limited - Hospira, Inc. - B. Braun Medical Inc. - Bayer Inc. - Actavis, Inc. - Hikma Pharmaceuticals PLC - Sandoz Inc. - Mutual Pharmaceutical Company, Inc. - Par Pharmaceutical Companies, Inc. - GlaxoSmithKline plc - Covis Pharmaceuticals, Inc - Pfizer Inc. - Sanofi - sanofi-aventis U.S. LLC. - King Pharmaceuticals Ltd - Pharmacia & Upjohn, Inc. - AstraZeneca PLC - Astellas Pharma US, Inc. - Baxter Healthcare Corporation - Abraxis BioScience, Inc. - GlaxoSmithKline Inc. - Wyeth Pharmaceuticals, Inc. - GlaxoSmithKline LLC - Warner Chilcott Plc - Wockhardt USA LLC - Hoffmann-La Roche Inc. - Dr. Reddy's Laboratories Inc. For more information visit http://www.researchandmarkets.com/research/39...espiratory
ACT: 298.98 (-2.94), PFE: 34.84 (+0.07), LLY: 78.59 (+0.08), BMY: 56.57 (-0.39), GSK: 43.82 (-0.17), MRK: 62.87 (-0.37), AZN: 33.18 (+0.09)
Allergan Reports Exceptional Second Quarter 2015 Performance with 116% Increase in Net Revenue to $5.76 Billion and 29% Growth in Non-GAAP EPS to $4.41
PR Newswire - Thu Aug 06, 6:00AM CDT
Allergan plc (NYSE: AGN) reported continued exceptional performance with net revenue increasing 116 percent to $5.76 billion for the quarter ended June 30, 2015, compared to $2.67 billion in the second quarter 2014. On a non-GAAP basis, diluted earnings per share increased 29 percent to $4.41 for the second quarter 2015, compared to $3.42 in the second quarter 2014. GAAP loss per share for the second quarter 2015 was $0.80, compared to GAAP income per diluted share of $0.28 in the prior year period. GAAP results were impacted by amortization, in-process research and development impairments, acquisition-related expenses, acquisition accounting valuation related expenses and severance and integration costs associated with acquired businesses, mainly the acquisitions of Allergan on March 17, 2015 and Forest Laboratories on July 1, 2014.
AGN: 238.42 (-0.70), ACT: 298.98 (-2.94)
Horizon Pharma plc Files Patent Infringement Lawsuits Against Five Companies for Filing Abbreviated New Drug Applications for PENNSAID(R) (Diclofenac Sodium Topical Solution) 2%
Marketwired - Mon Jul 06, 6:00AM CDT
Horizon Pharma plc (NASDAQ: HZNP), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, today announced it has filed patent infringement lawsuits in the United States District Court for the District of New Jersey against Actavis Laboratories UT, Inc., Actavis, Inc., and Allergan plc (collectively "Actavis" , Amneal Pharmaceuticals, LLC ("Amneal" , IGI Laboratories, Inc. ("IGI" , Lupin Ltd. and Lupin Pharmaceuticals, Inc. ("Lupin" , and Taro Pharmaceuticals USA, Inc. and Taro Pharmaceutical Industries, Ltd. (collectively "Taro" related to Abbreviated New Drug Applications filed with the U.S. Food and Drug Administration to market a generic version of PENNSAID(R) (diclofenac sodium topical solution) 2% w/w (PENNSAID 2%).
ACT: 298.98 (-2.94), HZNP: 17.83 (-0.07)
3 Generic Drug Stocks to Watch
Keith Speights, The Motley Fool - Motley Fool - Sun Jun 14, 2:03PM CDT
Source: Wikimedia Commons Every health insurer under the sun wants you to choose these types of product. So does every pharmacy benefits manager around. And going with them can save you plenty of money. What are these popular items? Generic...
LCI: 31.80 (+0.28), ACT: 298.98 (-2.94), SGNT: 21.76 (+0.03)
Wow! This Biotech IPO Doubled on Day One
Todd Campbell, The Motley Fool - Motley Fool - Sun Jun 14, 9:03AM CDT
Source: Axovant Sciences, Ltd. Shares in Axovant Sciences Ltd soared on their first day of trading, nearly doubling from their IPO price. There are, however, a lot of question marks associated with this instant biotech darling that investors...
ACT: 298.98 (-2.94), GSK: 43.82 (-0.17)
Aquinox Announces Executive Appointments
GlobeNewswire - Wed May 25, 8:15AM CDT
Aquinox Pharmaceuticals, Inc. ("Aquinox"
(NASDAQ:AQXP), a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology, is pleased to announce the appointment of Mrs. Abigail L. Jenkins as Chief Commercial Officer and Mr. Paul Brennan as Vice President, Business Development. Mrs. Jenkins will act as our US Business Head at our San Bruno, CA office and lead the design and implementation of the commercialization strategy for AQX-1125 while Mr. Brennan will be responsible for the identification and fostering of corporate alliances to support and compliment our global business strategies. ACT: 298.98 (-2.94), AQXP: 12.18 (+0.32), PFE: 34.84 (+0.07)
Supernus Enters Into Partial Settlement Agreement with Actavis on Oxtellar XR(R)
GlobeNewswire - Tue May 10, 7:30AM CDT
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, today announced that, pursuant to a confidential partial settlement agreement, it has dismissed two patent infringement actions pending in the U.S. District Court for the District of New Jersey against Actavis Inc. and its subsidiaries. The dismissed actions concerned two of Supernus' Orange Book patents covering Oxtellar XR(R)--U.S. Patent Nos. 8,821,930 and 9,119,791. The parties also agreed to dismiss Actavis' pending appeal (and Supernus' corresponding cross-appeal) of a February 2016 district court ruling that a third Oxtellar XR patent--U.S. Patent No. 8,617,600--is valid, but not infringed by Actavis' proposed generic version of Oxtellar XR. The February 2016 district court decision additionally found that Actavis infringed two other Oxtellar XR Orange Book patents (U.S. Patent Nos. 7,722,898 and 7,910,131), and enjoined Actavis from launching a generic version of Oxtellar XR until at least April 13, 2027. Actavis' appeal of that ruling will proceed as scheduled.
ACT: 298.98 (-2.94), SUPN: 22.51 (+0.32)
Global Human Reproductive Technologie Industry
PR Newswire - Tue Apr 05, 6:40PM CDT
This report analyzes the worldwide markets for Human Reproductive Technologies in US$ Million by the following Product Segments: Contraceptive Technologies, and Infertility Technologies. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Middle East & Africa, and Latin America. Annual estimates and forecasts are provided for the period 2014 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 102 companies including many key and niche players such as -
ACT: 298.98 (-2.94)
United States Pharmaceutical Preparation Market 2015 - Analysis And Forecast to 2020
M2 - Tue Jan 19, 6:27AM CST
Research and Markets (http://www.researchandmarkets.com/research/m9h77d/u_s) has announced the addition of the "U.S. Pharmaceutical Preparation Market - Analysis And Forecast to 2020" report to their offering. The report provides an in-depth analysis of the U.S. Pharmaceutical Preparation market. It presents the latest data of the market size and volume, domestic production, exports and imports, price dynamics and turnover in the industry. In addition, the report contains insightful information about the industry, including industry life cycle, business locations, productivity, employment and many other crucial aspects. The Company Profiles section contains relevant data on the major players in the industry. Product coverage: - Pharmaceutical preparations, affecting neoplasms, the endocrine system, and metabolic diseases, for human use - Pharmaceutical preparations, acting on the central nervous system and the sense organs, for human use - Pharmaceutical preparations, acting on the cardiovascular system, for human use - Pharmaceutical preparations, acting on the respiratory system, for human use - Pharmaceutical preparations, acting on the digestive or the genito-urinary systems, for human use - Pharmaceutical preparations, acting on skin, for human use - Pharmaceutical preparations, vitamin, nutrient, and hematinic preparations, for human use - Pharmaceutical preparations, affecting parasitic and infective diseases, for human use (excluding diagnostics) - Pharmaceutical preparations for veterinary use (including medicinal premixes and medicated pet care products, excluding pet flea and tick products), excluding diagnostics In vivo diagnostic substances Companies mentioned: - Pfizer Inc. - Merck & Co. - Abbott Laboratories - Abbvie Inc. - Eli Lilly and Company - Bristol-Myers Squibb Company - Genentech - Baxter International - Allergan - Biogen - Glaxosmithkline - Celgene Corporation - Hospira - Alere - Perrigo Company - Mylan Inc. - Regeneron Pharmaceuticals - Novartis Corporation - Alexion Pharmaceuticals - Genzyme Corporation - Zoetis - Sanofi US Services - Olympus Partners - Valeant Pharmaceuticals International - Merck Sharp & Dohme Corp. - Glaxosmithkline Holdings (americas) - Wyeth - Astrazeneca Pharmaceuticals - Actavis Inc. - Alcon Laboratories Holding Corporation - Roche Holdings Data coverage: - Market size; - Domestic production, value of shipments; - Key market players and their profiles; - Exports, imports and trade balance; - Import and export prices; - Forecast of the market dynamics in the medium term; - Key industry statistics; - Life cycle of the industry; - Number of establishments and their locations; - Employment data; - Industry productivity. For more information visit http://www.researchandmarkets.com/research/m9h77d/u_s
ABT: 41.90 (-0.26), PRGO: 90.39 (-1.68), ACT: 298.98 (-2.94), PFE: 34.84 (+0.07), LLY: 78.59 (+0.08), BMY: 56.57 (-0.39), VRX.TO: 39.05 (+1.19), AGN: 238.42 (-0.70), BAX: 45.90 (-0.05), MRK: 62.87 (-0.37), ALXN: 125.09 (-0.76), REGN: 399.89 (+1.58), NVS: 80.36 (+0.21), CELGZ: 1.20 (-0.05)
Human Reproductive Technologies Study 2015 - Global Strategic Business Report
M2 - Thu Jan 07, 9:35AM CST
Research and Markets (http://www.researchandmarkets.com/research/g69g82/human) has announced the addition of the "Human Reproductive Technologies - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Human Reproductive Technologies in US$ Million by the following Product Segments: Contraceptive Technologies, and Infertility Technologies. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Middle East & Africa, and Latin America. Annual estimates and forecasts are provided for the period 2014 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 102 companies including many key and niche players such as - Actavis, Inc. (US) - Ansell Limited (Australia) - Agile Therapeutics, Inc. (US) - Bayer HealthCare (Germany) - Church & Dwight Co., Inc. (US) - Cipla Limited (India) - CellCura ASA (Norway) - Cook Medical (US) - CooperSurgical (US) - Ferring Pharmaceuticals (Switzerland) - Fuji Latex Co., Ltd. (Japan) - Genea Biomedx (Australia) - Merck KGAA (Germany) - Okamoto Industries (Japan) - Pfizer Inc. (US) - Progyny, Inc. (US) - Reckitt Benckiser Group Plc. (UK) - Sanofi (US) - Teva Pharmaceutical Industries Ltd. (Israel) - The Female Health Company (US) Key Topics Covered: 1. INDUSTRY OVERVIEW 2. MARKET SEGMENTATION 3. INNOVATIONS IN THE HUMAN REPRODUCTIVE TECHNOLOGIES SPACE 4. TECHNOLOGY OVERVIEW 5. PRODUCT LAUNCHES/APPROVALS 6. RECENT INDUSTRY ACTIVITY 7. FOCUS ON SELECT GLOBAL PLAYERS 8. GLOBAL MARKET PERSPECTIVE Total Companies Profiled: 102 (including Divisions/Subsidiaries - 115) - The United States (28) - Canada (3) - Japan (3) - Europe (34) - - France (1) - - Germany (11) - - The United Kingdom (6) - - Italy (3) - - Rest of Europe (13) - Asia-Pacific (Excluding Japan) (41) - Latin America (3) - Africa (2) - Middle East (1) For more information visit http://www.researchandmarkets.com/research/g69g82/human
CHD: 49.13 (-1.18), ACT: 298.98 (-2.94), PFE: 34.84 (+0.07), TEVA: 51.29 (-0.04)
Emergency Medicine of the Future Demonstrated at ACEP15
PR Newswire - Tue Oct 27, 5:21PM CDT
Demonstrations by nearly 60 companies of cutting-edge technologies and devices are being featured this week in Boston during the ACEP 2015 Scientific Assembly where more than 6,500 emergency physicians are discussing the preeminent issues in emergency medicine and participating in educational courses. 2015 InnovatED is presented by Actavis, athenahealth, and Janssen Pharmaceuticals and allows participants to tour medical innovations in a unique emergency medicine environment.
ACT: 298.98 (-2.94)
Allergan Anti-Infective Portfolio Highlighted in 13 Abstracts at IDWeek 2015
PR Newswire - Thu Oct 08, 6:01AM CDT
Allergan plc (NYSE: ACT) today announced that its infectious disease portfolio will be featured in 13 abstracts highlighting data at IDWeek 2015, which takes place from October 7-11, 2015, in San Diego.
AGN: 238.42 (-0.70), ACT: 298.98 (-2.94), AZN: 33.18 (+0.09)
Cipher announces settlement in patent litigation for Absorica®
CNW Group - Mon Oct 05, 6:00AM CDT
Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company"
today announced that the Company, along with its partners, Ranbaxy Pharmaceuticals, Inc. ("Ranbaxy" , a Sun Pharma Company, and Galephar Pharmaceutical Research, Inc. ("Galephar" , have entered into a Settlement Agreement with Actavis Laboratories F1, Inc., Andrx Corp., Actavis, Inc. and Actavis Pharma, Inc. ("Actavis" that dismisses the patent litigation suit relating to Actavis' Abbreviated New Drug Application (ANDA) for a generic version of Absorica® (isotretinoin capsules). CPH.TO: 5.40 (+0.01), ACT: 298.98 (-2.94), CPHR: 4.26 (+0.06)
Depomed Files New Patent Infringement Lawsuit Against NUCYNTA(R) ER ANDA Filer
PR Newswire - Tue Sep 15, 7:00AM CDT
Depomed, Inc. (NASDAQ: DEPO) today announced that it has filed a new patent infringement lawsuit in the United States District Court for the District of New Jersey against Actavis Elizabeth LLC, Actavis, Inc. and Actavis LLC ("Actavis"
. Actavis previously filed an Abbreviated New Drug Application (ANDA) with the FDA to market generic Nucynta® ER (tapentadol hydrochloride, extended release) tablets and it served Paragraph IV certifications on the patents then listed in FDA's Orange Book for Nucynta® ER. At the time, Janssen Pharmaceuticals, Inc. owned the rights to Nucynta® ER and it filed a patent infringement suit against Actavis. Subsequently, U.S. Patent No. 8,536,130 ("'130 patent" issued and was listed in the Orange Book for Nucynta® ER, but Actavis did not file a Paragraph IV certification on this patent. In its new lawsuit, Depomed claims that Actavis's proposed generic product would infringe the '130 patent if its generic products are approved. The '130 patent does not expire until September 22, 2028, subject to additional exclusivity for pediatric studies. ACT: 298.98 (-2.94), DEPO: 21.79 (+0.70)
Global Parenteral Nutrition Industry
PR Newswire - Thu Aug 06, 3:32PM CDT
This report analyzes the worldwide markets for Parenteral Nutrition in US$ Million. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Middle East/Africa, and Latin America. Annual estimates and forecasts are provided for the period 2014 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 25 companies including many key and niche players such as -
ACT: 298.98 (-2.94)
Moderate Pain Market Analysis 2015 - Global API Manufacturers and Phase III Pipeline Assessment
M2 - Thu Aug 06, 10:08AM CDT
Research and Markets (http://www.researchandmarkets.com/research/qqg32p/moderate_pain) has announced the addition of the "Moderate Pain- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment" report to their offering. Moderate Pain- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014 provides comprehensive insights about phase III pipeline drugs and marketed drugs across the indication. A key objective of the report is to establish the understanding for API Manufacturers for marketed and Phase III pipeline drugs across the different countries and regions. While the leading brands, companies and chemicals are considered thoroughly, the report also provides details on the drug master filings across the US, Europe and Asia specifically China and India. The research, analysis also presents the global sales forecasts data till 2015. The report is also giving insight about the patent and exclusivity details of all the drugs across the indication. Key Topics Covered: - Indication Overview - Marketed Drugs Assessment - Marketed Details of Drugs by Application Type - Marketed Details of Drugs (NDA) by Marketing Status - Marketed Details of Drugs by Patent Expiration Timeline - The Active Pharmaceutical Ingredient (API) Manufacturers Assessment - The API Manufacturers by the United States Drug Master File (US DMF) Status - The API Manufacturers by the US DMF Status (Drug Specific) - The Active Pharmaceutical Ingredient (API) Manufacturers Assessment for Phase III Pipeline Drugs - The API Manufacturers by the US DMF Status (Drug Specific) - Drugs Market Data and Forecasted Sales Figures (2011-2015) - Marketed Drugs Information - Drugs Description - Route of Synthesis - Global Active Pharmaceutical Manufacturers - Approval Status - Patent and Exclusivity Details - Company Overview - Phase III Drugs Information - Phase III Drugs Description - The United States Drug Master Filings (US DMF) - Discontinued Drugs Information Companies Mentioned - Pfizer Inc. - Janssen Pharmaceutica, Inc. - Purdue Pharma L.P. - Prasco Laboratories - American Regent, Inc. - Caraco Pharmaceutical Laboratories, Ltd. - Merck & Co., Inc. - Novartis Pharmaceuticals Corporation - Actavis Inc. - Mallinckrodt Pharmaceuticals Generics - Shionogi Inc. - Mylan Inc. - Hospira, Inc. - Medicis Pharmaceutical Corporation For more information visit http://www.researchandmarkets.com/research/qq...erate_pain
ACT: 298.98 (-2.94), PFE: 34.84 (+0.07), MRK: 62.87 (-0.37), NVS: 80.36 (+0.21)
Lower Respiratory Tract Infections Market Analysis 2015 - Global API Manufacturers and Phase III Pipeline Assessment
M2 - Thu Aug 06, 9:52AM CDT
Research and Markets (http://www.researchandmarkets.com/research/396bfs/lower_respiratory) has announced the addition of the "Lower Respiratory Tract Infections- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment" report to their offering. Lower Respiratory Tract Infections- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014 provides comprehensive insights about phase III pipeline drugs and marketed drugs across the indication. A key objective of the report is to establish the understanding for API Manufacturers for marketed and Phase III pipeline drugs across the different countries and regions. While the leading brands, companies and chemicals are considered thoroughly, the report also provides details on the drug master filings across the US, Europe and Asia specifically China and India. The research, analysis also presents the global sales forecasts data till 2015. The report is also giving insight about the patent and exclusivity details of all the drugs across the indication. Reasons to buy - Evaluate the marketing status and exclusivity details of Lower Respiratory Tract Infections key products to exploit opportunities for generic drug development opportunities. - Identify and understand important and diverse types of therapeutics under Phase III development for Lower Respiratory Tract Infections. - Design effective counter-strategies to gain competitive advantage by identifying the key patent expiry details and exclusivity with respect to Lower Respiratory Tract Infections. - API intelligence over marketed drugs for Lower Respiratory Tract Infections and gaining primary intelligence over active ingredients manufacturers across the globe. - API intelligence over leading Phase III pipeline drugs. - Develop and designstrategies by identifying the API manufacturers for Phase III pipeline products to enhance and expand business potential and scope. - Understanding the scope of the Phase III Drugs with nil regulatory filings. - Understanding the chemical route of synthesis of approved drugs for Lower Respiratory Tract Infections. - Uncovering opportunities in the rapidly growing the US markets. Companies Mentioned - Merck & Co., Inc. - Dr. Reddy's Laboratories Limited - Corden Pharma International GmbH - Eli Lilly and Company - Genentech, Inc. - Arbor Pharmaceuticals, Inc. - Bayer AG - Bristol-Myers Squibb Company - Mayne Pharma Limited - Hospira, Inc. - B. Braun Medical Inc. - Bayer Inc. - Actavis, Inc. - Hikma Pharmaceuticals PLC - Sandoz Inc. - Mutual Pharmaceutical Company, Inc. - Par Pharmaceutical Companies, Inc. - GlaxoSmithKline plc - Covis Pharmaceuticals, Inc - Pfizer Inc. - Sanofi - sanofi-aventis U.S. LLC. - King Pharmaceuticals Ltd - Pharmacia & Upjohn, Inc. - AstraZeneca PLC - Astellas Pharma US, Inc. - Baxter Healthcare Corporation - Abraxis BioScience, Inc. - GlaxoSmithKline Inc. - Wyeth Pharmaceuticals, Inc. - GlaxoSmithKline LLC - Warner Chilcott Plc - Wockhardt USA LLC - Hoffmann-La Roche Inc. - Dr. Reddy's Laboratories Inc. For more information visit http://www.researchandmarkets.com/research/39...espiratory
ACT: 298.98 (-2.94), PFE: 34.84 (+0.07), LLY: 78.59 (+0.08), BMY: 56.57 (-0.39), GSK: 43.82 (-0.17), MRK: 62.87 (-0.37), AZN: 33.18 (+0.09)
Allergan Reports Exceptional Second Quarter 2015 Performance with 116% Increase in Net Revenue to $5.76 Billion and 29% Growth in Non-GAAP EPS to $4.41
PR Newswire - Thu Aug 06, 6:00AM CDT
Allergan plc (NYSE: AGN) reported continued exceptional performance with net revenue increasing 116 percent to $5.76 billion for the quarter ended June 30, 2015, compared to $2.67 billion in the second quarter 2014. On a non-GAAP basis, diluted earnings per share increased 29 percent to $4.41 for the second quarter 2015, compared to $3.42 in the second quarter 2014. GAAP loss per share for the second quarter 2015 was $0.80, compared to GAAP income per diluted share of $0.28 in the prior year period. GAAP results were impacted by amortization, in-process research and development impairments, acquisition-related expenses, acquisition accounting valuation related expenses and severance and integration costs associated with acquired businesses, mainly the acquisitions of Allergan on March 17, 2015 and Forest Laboratories on July 1, 2014.
AGN: 238.42 (-0.70), ACT: 298.98 (-2.94)
Horizon Pharma plc Files Patent Infringement Lawsuits Against Five Companies for Filing Abbreviated New Drug Applications for PENNSAID(R) (Diclofenac Sodium Topical Solution) 2%
Marketwired - Mon Jul 06, 6:00AM CDT
Horizon Pharma plc (NASDAQ: HZNP), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, today announced it has filed patent infringement lawsuits in the United States District Court for the District of New Jersey against Actavis Laboratories UT, Inc., Actavis, Inc., and Allergan plc (collectively "Actavis"
, Amneal Pharmaceuticals, LLC ("Amneal" , IGI Laboratories, Inc. ("IGI" , Lupin Ltd. and Lupin Pharmaceuticals, Inc. ("Lupin" , and Taro Pharmaceuticals USA, Inc. and Taro Pharmaceutical Industries, Ltd. (collectively "Taro" related to Abbreviated New Drug Applications filed with the U.S. Food and Drug Administration to market a generic version of PENNSAID(R) (diclofenac sodium topical solution) 2% w/w (PENNSAID 2%). ACT: 298.98 (-2.94), HZNP: 17.83 (-0.07)
3 Generic Drug Stocks to Watch
Keith Speights, The Motley Fool - Motley Fool - Sun Jun 14, 2:03PM CDT
Source: Wikimedia Commons Every health insurer under the sun wants you to choose these types of product. So does every pharmacy benefits manager around. And going with them can save you plenty of money. What are these popular items? Generic...
LCI: 31.80 (+0.28), ACT: 298.98 (-2.94), SGNT: 21.76 (+0.03)
Wow! This Biotech IPO Doubled on Day One
Todd Campbell, The Motley Fool - Motley Fool - Sun Jun 14, 9:03AM CDT
Source: Axovant Sciences, Ltd. Shares in Axovant Sciences Ltd soared on their first day of trading, nearly doubling from their IPO price. There are, however, a lot of question marks associated with this instant biotech darling that investors...
ACT: 298.98 (-2.94), GSK: 43.82 (-0.17)
(0)
(0)Scroll down for more posts ▼